Recent Examples on the WebThe pills are only available for nonhospitalized patients at high risk of developing severe covid, for the disabled and for older Americans. Jeannie Roberts, Arkansas Online, 17 Apr. 2022 The Food and Drug Administration on Friday cleared the drug, bebtelovimab, for the treatment of mild to moderate Covid-19 in nonhospitalized individuals 12 and older who are at high risk of getting severely sick. Peter Loftus, WSJ, 11 Feb. 2022 The drug requires three consecutive IV infusions over three days, when used for nonhospitalized patients.NBC News, 25 Jan. 2022 The drug requires three consecutive IV infusions over three days, when used for nonhospitalized patients.CBS News, 25 Jan. 2022 Veklury was just authorized for use in nonhospitalized patients. Felicia Schwartz, WSJ, 22 Jan. 2022 In these situations, Boulware suggests considering fluvoxamine or budesonide—widely available, low-cost drugs for other conditions that have published data suggesting benefits in nonhospitalized COVID patients. Esther Landhuis, Scientific American, 21 Jan. 2022 The National Institutes of Health says that monoclonal antibodies can be used to treat mild to moderate COVID-19 in nonhospitalized patients at high risk for progressing to severe disease.Los Angeles Times, 7 Dec. 2021 The researchers cautioned that the findings may not translate to nonhospitalized people with different levels of access to medical care, and that some patients in the vaccinated group may unknowingly have also had previous infections.BostonGlobe.com, 30 Oct. 2021 See More